Pharmion acquires Innohep
Executive Summary
Pharmion will sell the low molecular weight heparin product Innohep (tinzaparin) after acquiring U.S. rights from Danish firm LEO Pharma. DuPont returned Innohep rights after the company's acquisition by Bristol-Myers Squibb...
You may also be interested in...
Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder
Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.